Istradefylline

NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.

Side effects, and when to stop

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

Dyskinesia
Hallucinations / Psychotic Behavior
Impulse Control / Compulsive Behaviors

Who should not take it

None.

Storing it

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F to 86°F).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Istradefylline; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/istradefylline
APA 7th: sofidex. (2026, August 3). Istradefylline. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/istradefylline
AMA 11th: Istradefylline. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/istradefylline

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.